Prosecution Insights
Last updated: April 19, 2026
Application No. 18/295,520

CONTACT LENS COMPOSITIONS AND METHODS OF USE THEREOF

Non-Final OA §102
Filed
Apr 04, 2023
Examiner
PALLAY, MICHAEL B
Art Unit
1617
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Ps Therapy Inc.
OA Round
1 (Non-Final)
56%
Grant Probability
Moderate
1-2
OA Rounds
3y 3m
To Grant
91%
With Interview

Examiner Intelligence

Grants 56% of resolved cases
56%
Career Allow Rate
396 granted / 707 resolved
-4.0% vs TC avg
Strong +35% interview lift
Without
With
+35.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
59 currently pending
Career history
766
Total Applications
across all art units

Statute-Specific Performance

§101
1.5%
-38.5% vs TC avg
§103
46.2%
+6.2% vs TC avg
§102
13.2%
-26.8% vs TC avg
§112
23.4%
-16.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 707 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group III (claims 14-15) in the reply filed on 19 August 2025 is acknowledged. Claims 1-13 and 16-22 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected inventions, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 19 August 2025. Claims 14-15 are under current consideration. Claim Objections Claims 14-15 are objected to because of the following informalities: they depend upon claim 1 which is withdrawn. Appropriate correction is required. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 14-15 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Horn ‘006 (US 8,933,006 B1; issued 13 January 2015). Regarding claims 14-15, Horn ‘006 discloses a contact lens cleaning composition comprising 5.00% w/v polyoxyl 40 stearate, 0.20% w/v poloxamer 407, 0.10% w/v poloxamer 188, and NaCl (Table 1 Composition 15), reading on the claimed contact lens storage composition comprising one or more nonionic surfactants selected from polyoxyls and poloxamers at a total concentration from about 1.5% to about 5.9% w/v and sodium chloride, given that the claimed term “storage” merely implies an intended use of the composition that imposes no structure or steps not otherwise recited in the claim, and given that the total concentration of polyoxyl 40 stearate, poloxamer 407, and poloxamer 188 nonionic surfactants is 5.3% w/v (i.e., 5% + 0.20% + 0.10% w/v). Further regarding claims 14-15, Horn ‘006 discloses that the composition of Table 1 is instilled as drops to contact lens wearers complaining of dry, uncomfortable lenses after 16 hours of continuous contact lens use which provided long-lasting relief upon instillation with improved comfort (column 5 lines 5-14) wherein the method of the invention is directed to a method of cleaning a contact lens while the contact lens remains on the eye (column 1 lines 5-14), reading on the claimed method of enhancing contact lens comfort comprising administering the composition to a subject in need thereof of claim 14 and the claimed method of enhancing contact lens wear time comprising administering the composition to a subject in need thereof of claim 15. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHAEL B. PALLAY whose telephone number is (571)270-3473. The examiner can normally be reached Monday through Friday from 8:30 AM to 5:00 PM Eastern Time. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sue Liu can be reached at (571)272-5539. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICHAEL B. PALLAY/Primary Examiner, Art Unit 1617
Read full office action

Prosecution Timeline

Apr 04, 2023
Application Filed
Nov 26, 2025
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12582603
OPHTHALMIC PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF BRINZOLAMIDE AND BRIMONIDINE AND METHOD OF PREPARATION THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12577244
HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING COMPOSITION CONTAINING SAME
2y 5m to grant Granted Mar 17, 2026
Patent 12532883
Powder Compositions Comprising Salts of C4 to C10 Oxocarboxylic Acids and of Unsaturated or Aromatic C6 to C10 Carboxylic Acids
2y 5m to grant Granted Jan 27, 2026
Patent 12533377
PREVENTIVE AND CURATIVE PEROXOMETALLATE BASED COMPOSITION, NOTABLY PHARMACEUTICAL COMPOSITION
2y 5m to grant Granted Jan 27, 2026
Patent 12527752
COMPOSITION BASED ON GELLAN GUM AND PHENYLEPHRINE, PRODUCTION METHOD AND USE AS AN OPHTHALMIC PRODUCT
2y 5m to grant Granted Jan 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
56%
Grant Probability
91%
With Interview (+35.0%)
3y 3m
Median Time to Grant
Low
PTA Risk
Based on 707 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month